Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vir Biotechnology Inc
(NQ:
VIR
)
9.730
-0.200 (-2.01%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
644,741
Open
9.940
Bid (Size)
9.600 (1)
Ask (Size)
10.03 (5)
Prev. Close
9.930
Today's Range
9.610 - 10.07
52wk Range
7.610 - 26.14
Shares Outstanding
133,976,538
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
May 07, 2024
Via
Benzinga
VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024
May 02, 2024
VIR stock results show that Vir Biotechnology beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Performance
YTD
-7.42%
-7.42%
1 Month
+17.94%
+17.94%
3 Month
-5.07%
-5.07%
6 Month
+0.41%
+0.41%
1 Year
-62.52%
-62.52%
More News
Read More
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 02, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
April 30, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
April 18, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Assessing Vir Biotechnology: Insights From 5 Financial Analysts
March 15, 2024
Via
Benzinga
Recap: Vir Biotechnology Q4 Earnings
February 22, 2024
Via
Benzinga
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
April 11, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
March 19, 2024
Via
InvestorPlace
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
March 13, 2024
Via
InvestorPlace
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
March 05, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Earnings Outlook For Vir Biotechnology
February 21, 2024
Via
Benzinga
JP Morgan Downgrades Vir Biotechnology: Here's What You Need To Know
January 29, 2024
Via
Benzinga
3 Highly Rated Biotech Stocks to Buy for 300% Gains
February 26, 2024
Via
InvestorPlace
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 23, 2024
Via
Benzinga
Carvana Posts Q4 Results, Joins LegalZoom.com, Comfort Systems And Other Big Stocks Moving Higher On Friday
February 23, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
February 23, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
February 22, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer
February 20, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave
February 14, 2024
Via
InvestorPlace
Earnings Scheduled For February 22, 2024
February 22, 2024
Via
Benzinga
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
February 01, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
HC Wainwright & Co. Maintains Buy Rating for Vir Biotechnology: Here's What You Need To Know
January 23, 2024
Via
Benzinga
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
December 20, 2023
Via
Benzinga
Exposures
COVID-19
Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation
December 13, 2023
From
Vir Biotechnology, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.